Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
Clinical trial NCT01673854 · COMPLETED
Trial details
- NCT number
- NCT01673854
- Sponsor
- Bristol-Myers Squibb
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2012-09-13
- Primary completion
- 2014-07-25
- Enrollment
- 70
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.